627 related articles for article (PubMed ID: 1975512)
1. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
2. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells.
Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M
J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
Schmidt-Wolf IG; Lefterova P; Johnston V; Scheffold C; Csipai M; Mehta BA; Tsuruo T; Huhn D; Negrin RS
Cell Immunol; 1996 Apr; 169(1):85-90. PubMed ID: 8612299
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
[TBL] [Abstract][Full Text] [Related]
7. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
Zheng YJ; Zhang J; Wang SM; Zhang JR
Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D
Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells.
Komatsu F; Yoshida S
Oncol Res; 1999; 11(5):213-8. PubMed ID: 10608615
[TBL] [Abstract][Full Text] [Related]
11. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
12. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
13. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
15. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
18. Reduction of susceptibility to NK lysis in cisplatin-resistant K562 cell lines.
Dedoussis G; Menounos P; Papadopoulos N; Gounaris A; Karameris A
Anticancer Res; 1998; 18(4C):3081-5. PubMed ID: 9713514
[TBL] [Abstract][Full Text] [Related]
19. Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression.
Classen CF; Falk CS; Friesen C; Fulda S; Herr I; Debatin KM
Haematologica; 2003 May; 88(5):509-21. PubMed ID: 12745270
[TBL] [Abstract][Full Text] [Related]
20. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.
Yanovich S; Hall RE; Weinert C
Cancer Res; 1986 Sep; 46(9):4511-5. PubMed ID: 2425955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
